N@N

Theragenics to Report Fourth Quarter and Year-End 2010 Financial Results Tuesday, February 15

_{//health-fitness.news-articles.net/content/2011/ .. -2010-financial-results-tuesday-february-15.html}
^{Published in Health and Fitness on Thursday, February 10th 2011 at 4:20 GMT by Market Wire}  

BUFORD, Ga.--([ BUSINESS WIRE ])--Theragenics Corporation^® (NYSE: TGX) expects to release fourth quarter and year-end 2010 consolidated financial results before the market opens on February 15, 2011. Following this release, the Company will host a conference call at 11:00 a.m. Eastern.

To participate in the call, dial 877-407-4019 or 201-689-8337. The call is also being webcast and can be accessed via Theragenicsa™ website, [ www.theragenics.com ]. A replay will be available on the website for one month. A phone replay will be available until Midnight, February 22, 2011 by dialing 877-660-6853 or 201-612-7415, and entering the account # 372 and conference ID 367185.

Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business ([ www.cpmedical.com ], [ www.galtmedical.com ], [ www.needletech.com ]) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. The surgical products segment serves a number of markets and applications, including, among others, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenicsa™ brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed^® device ([ www.theraseed.com ]) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer.